Insider buying last 90 days
No open-market insider purchases were filed for RVTY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RVTY insider filing, plotted on the chart in Gekko.Open RVTY in Gekko
NYSE: RVTY
Revvity (RVTY) Stock Analysis & Forecast
Sep 28 close
$151.02−0.09 (−0.1%)
Gekko Brief
AI summaryRevvity's week centers on the launch of its GSP T1D 3plex kit, a CE-IVDR-certified, fully automated screening test for early detection of type 1 diabetes in children, using dried blood spot samples on the company's GSP instrument platform. The product also appears alongside a mention of an intended acquisition of Human Cell Design, a company focused on human cell models for metabolic diseases. Coverage also revisits the Q2 2026 earnings call, in which Revvity reported pro forma organic growth of 3%, revenue above the high end of guidance, and adjusted EPS of $1.41 against a $1.21 estimate, aided by tax timing and tariff refunds.
Shares closed at $151.02, down 0.1% on the day, sitting above both the 50-day average of $124.50 and the 200-day average of $105.26, with the 52-week high at $152.26. The GekkoIndex reads 44.6, placing the stock in the Distribution zone. Price stands 40.8% above the Gekko Fair Value of $107.24.
Over the next 20 trading days, the earnings date of 26 October falls inside that window, following a prior quarter where EPS beat estimates and the stock reaction was -0.2%. Smart-money activity shows 2 unusual options signals in the last 30 days, with call premium of $913,645 against no put premium. Seasonality over 5 years shows an average 20-day return of 1.4%, rising in 2 of those years. Analyst consensus among 10 firms includes 4 buy and 6 hold ratings, with a consensus target of $129.35.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Revvity price vs fair value
Close $151.02200-day averageGekko Fair Value $107.24
Revvity quick facts
- Market cap
- $16.85B
- P/E ratio
- 68.5
- Forward P/E
- 24.2
- EPS, TTM
- $2.20
- Revenue, TTM
- $2.91B
- Profit margin
- 8.2%
- Dividend yield
- 0.20%
- Beta
- 1.09
- Volume
- 1.48M avg 2.18M
- 1-year return
- +81.9%
- Typical daily move
- ±3.5%
- Typical 20-day move
- ±5.7%
- 50-day average
- $124.50
- 200-day average
- $105.26
- Next earnings
- Oct 26 before open
- Shares outstanding
- 111.6M
Revvity swing-trade checklist
Revvity scores 2 supportive, 1 mixed and 3 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $151.02 is above the 50-day ($124.50) and 200-day ($105.26) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
44.6, Distribution
Reading 44.6 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
40.8% above
Price is 40.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 2 unusual options signals.
See smart money - Earnings riskheadwind
Reports in 27 days
Reports on Oct 26, 2026, 27 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.4% on average
From this point in the calendar, the next 20 trading days averaged +1.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Revvity stock chart and price history
Revvity closed at $151.02 on Sep 28, 2026, +81.9% over the past year, inside a 52-week range of $81.22 to $152.26.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +16.4%
- 3 months
- +35.8%
- 6 months
- +80.0%
- 1 year
- +81.9%
The full RVTY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RVTY in Gekko
Follow Revvity through every session
Put RVTY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RVTY in GekkoFree for 7 days. No credit card required.
About Revvity
Revvity supplies instruments, reagents, software and related services used in scientific research and health screening. The company works across life sciences and diagnostics, offering tools such as detection and imaging technology, laboratory instrumentation, and testing platforms used to identify genetic and infectious conditions. It is recognized for products that support screening for disorders such as Down syndrome and metabolic conditions, as well as tools used in genomic research.
The company operates through two main areas. One focuses on instruments, reagents, informatics and contract laboratory work for life sciences research, environmental testing, agriculture and food analysis, and industrial applications like chemicals, semiconductors and energy. The other centers on diagnostics, providing assay systems and sequencing-based tools used in prenatal and childhood screening, infectious disease testing, oncology and drug discovery. Its customers include pharmaceutical and biotechnology firms, laboratories, academic institutions, healthcare providers, public health agencies and government organizations.
Revvity's shares are listed on the NYSE under the ticker RVTY.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- revvity.com
Revvity GekkoIndex: the smart money zone
Revvity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 44.6, in the Distribution zone, up 1.6 points over five sessions.
44.6Distribution
Up 1.6 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +1.8% | +2.8% | ||
| Accumulation | 251 | +0.5% | +1.2% | ||
| Neutral | 366 | +0.3% | +1.4% | ||
| Distribution (current zone) | 35 | −1.6% | −4.4% | ||
| Selling | 1 | Too few readings yet | |||
Average RVTY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the RVTY price, zone by zone.Track RVTY in Gekko
Is Revvity stock overvalued? Gekko Fair Value
Revvity trades 40.8% above Gekko Fair Value of $107.24, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Revvity shares are worth, recalculated every trading day.
$107.24
Gekko Fair Value, Sep 26, 2026
40.8% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RVTY in Gekko
Revvity insider and Congress trading
No open-market insider purchases were filed for Revvity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RVTY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RVTY, plotted on the chart in Gekko.Open RVTY in Gekko
Buybacks
Revvity has been buying back its own shares.
- Bought back, quarter ended Jul 5, 2026
- $15.99M
- As a share of market cap
- 0.09%
- Trailing four quarters
- $475.8M
From company filings.
Unusual options activity last 30 days
2signals, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 25, $416K in unusual premium.
Every signal with its contract, strike and premium.Unlock in Gekko
Revvity earnings: next date and track record
Revvity reports on Oct 26, 2026, before the open (27 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 26, 2026
Expected before the open, 27 days away
- EPS estimate
- $1.28
- Revenue estimate
- $694.4M
8 of 8reports beat the EPS estimate
±5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Revvity reported Q2 2026 pro forma organic growth of 3%, with total revenue above guidance high end and adjusted EPS of $1.41 significantly beating expectations due to operating performance, tax timing, and tariff refunds. Pharma/biotech end markets showed third consecutive quarter of improvement. AI-driven demand boosted high-content screening instruments including the Opera Phenix OptIQ with double-digit growth. Company signed definitive agreement to divest China immunodiagnostics business.
- Guidance
- Management raised full-year pro forma guidance for organic growth, adjusted operating margin, and adjusted EPS based on stronger Q2 performance and improved second-half optimism. Higher-than-normal instrument backlog exiting Q2 provides favorable positioning for H2.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $1.41 est $1.21 | $711.0M est $703.0M | −0.2% |
| May 5, 2026 | $1.06 est $1.02 | $711.1M est $704.1M | +14.5% |
| Feb 2, 2026 | $1.70 est $1.57 | $772.1M est $764.9M | −7.0% |
| Oct 27, 2025 | $1.18 est $1.14 | $698.9M est $699.4M | −2.5% |
| Jul 28, 2025 | $1.18 est $1.14 | $720.3M est $699.9M | −8.9% |
| Apr 28, 2025 | $1.01 est $0.96 | $664.8M est $710.8M | +0.4% |
| Jan 31, 2025 | $1.42 est $1.38 | $729.4M est $665.3M | −2.5% |
| Nov 4, 2024 | $1.28 est $1.13 | $684.0M est $679.7M | +4.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Revvity stock forecast and analyst price targets
Analysts’ average 12-month price target for Revvity is $129.35, −14.3% from the last close, from 10 firms rating the stock in the last 90 days.
$129.35consensus 12-month target, −14.3% from the last close
Now $151.02Avg $129.35
Low $110High $165
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Bernstein | $120 | −20.5% |
| Sep 18 | CFRA | — | — |
| Sep 9 | Bernstein | $120 | −20.5% |
| Sep 9 | UBS | $140 | −7.3% |
| Sep 4 | KeyBanc | $165 | +9.3% |
−4.4%average 20-day move after past Distribution readings
+1.4%average move over the next 20 trading days in the last 5 years
±3.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Revvity seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Revvity averaged +1.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.1% | 2 of 5 |
| Next 10 trading days | −0.8% | 1 of 5 |
| Next 15 trading days | +0.9% | 3 of 5 |
| Next 20 trading days | +1.4% | 2 of 5 |
| Next 30 trading days | −0.8% | 3 of 5 |
For scale, RVTY’s typical 20-trading-day move in either direction is about 5.7%.
Revvity market cap and key statistics
Revvity’s market cap is $16.85B, with a P/E ratio of 68.5 and revenue of $2.91B over the last twelve months.
Valuation
- Market cap
- $16.85B
- P/E ratio
- 68.5
- Forward P/E
- 24.2
- EPS, TTM
- $2.20
- Gekko Fair Value
- $107.24
Trading
- Volume
- 1.48M
- Avg volume, 20 days
- 2.18M
- 52-week high
- $152.26
- 52-week low
- $81.22
- Shares outstanding
- 111.6M
Financials
- Revenue, TTM
- $2.91B
- Profit margin
- 8.2%
- Return on equity
- 3.2%
- Quarterly earnings growth, YoY
- +1.2%
Risk and income
- Beta
- 1.09
- Typical daily move
- ±3.5%
- Typical 20-day move
- ±5.7%
- Dividend yield
- 0.20%
Revvity stock news this week
Coverage of Revvity this week reads positive: 11 positive, 8 neutral and 1 negative headlines.
- Revvity (RVTY) Launches T1D Screening Kit, Is The Upside Already Priced In?Simply Wall Street, Sep 28
- Revvity stock last trades at USD 150.00 on September 28, 2026AD HOC NEWS, Sep 28
- Revvity Launches IVDR-Certified Triplex Autoantibody Assay for Early Type 1 Diabetes ScreeningClinical Lab Products, Sep 28
- Did Diabetes Screening Kit Launch Just Shift Revvity (RVTY) Stock Investment Narrative?Simply Wall Street, Sep 26
- New Products: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, AgilentGenomeWeb, Sep 25
- RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes DetectionYahoo Finance Singapore, Sep 25
Revvity peers
Revvity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Revvity stock FAQ
What is Revvity’s market cap?
Revvity’s market cap is $16.85B at the Sep 28, 2026 close of $151.02, with 111.6M shares outstanding. The shares trade on a P/E ratio of 68.5.
What is the Revvity stock forecast?
The consensus analyst 12-month price target for Revvity is $129.35, −14.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 4 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Revvity stock overvalued or undervalued?
On Gekko’s estimate Revvity is overvalued: the Sep 28, 2026 close of $151.02 is 40.8% above Gekko Fair Value of $107.24. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Revvity report earnings next?
Revvity is expected to report on Oct 26, 2026, before the market opens (27 days away). Analysts expect earnings of $1.28 per share on revenue of $694.4M. Revvity beat the earnings estimate in 8 of its last 8 reports, moving 5% on average across the report.
What is Revvity’s 52-week high and low?
Revvity’s 52-week high is $152.26 and its 52-week low is $81.22; it closed at $151.02 on Sep 28, 2026, +81.9% over the past year. Over the last five years the shares peaked at $203.16 on Dec 31, 2021.
Is Revvity stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and smart money), 1 as mixed (seasonality) and 3 as headwinds (gekkoindex, fair value and earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Revvity?
Gekko flagged 2 unusual options signals in Revvity over the last 30 days, with $914K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 25, 2026 with $416K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Revvity the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.